Preferential use of vein for above-knee femoropopliteal grafts

Wilson, Y.G.; Wyatt, Michael G.; Currie, I.C.; Baird, RN; Lamont, PM

doi:10.1016/s1078-5884(05)80116-9

Cited by 35 publications

(15 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Wilson et al make an effective argument against preferential use of prosthetic grafts. 10 They examined their series of 112 above-knee femoropopliteal bypass grafts and concluded that the 3-year results were superior for autogenous vein, that the amputation rate after graft failure was significantly higher when Gore-tex was used, and that the secondary vein was only rarely needed after Gore-tex failure. The strong evidence that small-diameter grafts have a greater risk of occlusion is counterintuitive.…”

Section: Discussionmentioning

confidence: 99%

Prosthetic above-knee femoropopliteal bypass grafting: Five-year results of a randomized trial

Green

Abbott²,

Matsumoto³

et al. 2000

Journal of Vascular Surgery

151

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Prosthetic above-knee femoropopliteal bypass grafting: Five-year results of a randomized trial

Green

Abbott²,

Matsumoto³

et al. 2000

Journal of Vascular Surgery

151

View full text Add to dashboard Cite

show abstract

“…Recently, a great deal of research work has focused on developing biodegradable polymeric 390 L. Ye et al / Journal of Biomaterials Science 22 (2011) [389][390][391][392][393][394][395][396][397][398][399][400][401][402][403][404][405][406] scaffolds with mechanical properties appropriate for application in the vascular tissue engineering [3]. However, in small-diameter arterial replacements, TE vascular grafts often fail due to their unsatisfactory patency resulting from early thrombosisrelated occlusion caused by imperfect endothelium layers [2,[4][5][6]. How to maintain long-term patency of these small-diameter vascular grafts remains a significant challenge in vascular tissue engineering.…”

Section: Introductionmentioning

confidence: 99%

Heparin-Conjugated PCL Scaffolds Fabricated by Electrospinning and Loaded with Fibroblast Growth Factor 2

Mei

et al. 2011

Journal of Biomaterials Science, Polymer Edition

View full text Add to dashboard Cite

A biodegradable poly(ε-caprolactone) (PCL) was synthesized by ring-opening polymerization of ε-caprolactone catalyzed by Sn(Oct)2/BDO, followed by the heparin conjugation using EDC/NHS chemistry. The structure of the heparin-PCL conjugate was characterized by (1)H-NMR and GPC. The results of static contact angle and water uptake ratio measurements also confirmed the conjugation of heparin with the polyester. Its in vitro anticoagulation time was substantially extended, as evidenced by activated partial thromboplastin time (APTT) testing. Afterwards the conjugate was electrospun into small-diameter tubular scaffolds and loaded with Fibroblast Growth Factor 2 (FGF2) in aqueous solution. The loading efficiency was assayed by enzyme-linked immunosorbent assay (ELISA); the results indicated that the conjugate holds a higher loading efficiency than the blank polyester. The viability of released FGF2 was evaluated by MTT and cell adhesion tests. The amount and morphology of cells were significantly improved after FGF2 loading onto the electrospun heparin-PCL vascular scaffolds.

show abstract

“…This is due to some authors reporting results with the use of prosthetic graft being equivalent to the use of autologous vein graft, [7][8][9][10] and because others advocated the use of autologous vein both for above and below knee (BK) arterial reconstruction. 11,12 Otherwise, for infrageniculate arterial bypass, the opinion that autologous vein is the best conduit is widely accepted. 13,14 However, patients with arteriosclerosis obliterans (ASO) can suffer from potential ischemic heart disease (IHD) concomitantly and they need to undergo some interventional coronary angioplasty and/ or coronary bypass surgery.…”

Section: Introductionmentioning

confidence: 99%

Long Term Outcome of Femoropopliteal Bypass for Claudication and Critical Ischemia

Kobayashi

Hida

Shikata

et al. 2004

Asian Cardiovasc Thorac Ann

View full text Add to dashboard Cite

We performed 167 femoropopliteal bypass surgeries in 151 patients (95 patients underwent above-knee bypass and 56 below-knee bypass) from December 1985 to December 2000 with the use of prosthetic graft or autologous vein graft. We compared primary patency rates between age, sex, graft material, distal anastomotic site and severity of ischemia, considering their survival rates to elucidate the long-term outcome of above-knee and below-knee femoropopliteal bypass. The 10 year patency rate for above-knee bypass was 47.4%, compared to 36.9% for below-knee ( p < 0.01). Better results were found after bypass surgery for claudicants than for critical ischemia ( p < 0.05). With regard to graft material and age categories, there were unexpectedly no statistical differences in either above-knee or below-knee anastomosis. The survival rate at 10 years in claudicants was 51.2%, compared to 15.9% with critical ischemia ( p < 0.01). Mortality was much influenced by ischemic heart disease ( p < 0.002) and the age of patient ( p < 0.05). The results after above-knee bypass had comparable patency, whereas the results after below-knee bypass were disappointing. Below-knee arterial reconstruction for claudicants should be carefully considered and might be recommended only to patients with critical ischemia.

show abstract

Preferential use of vein for above-knee femoropopliteal grafts

Abstract: The demand for vein for secondary procedures is low. Amputation rates when vein grafts do occlude are half those of PTFE and amputation level is significantly influenced by graft type. We advocate preferential use of vein in above-knee femoropopliteal bypass.

Cited by 35 publications

References 15 publications

Prosthetic above-knee femoropopliteal bypass grafting: Five-year results of a randomized trial

Prosthetic above-knee femoropopliteal bypass grafting: Five-year results of a randomized trial

Heparin-Conjugated PCL Scaffolds Fabricated by Electrospinning and Loaded with Fibroblast Growth Factor 2

Long Term Outcome of Femoropopliteal Bypass for Claudication and Critical Ischemia

Contact Info

Product

Resources

About